Email Updates

You are here

23 MARCH 2018 VOLUME 19 ISSUE 12

Media Coverage

  • In The Lancet Infectious Diseases, Ravindra Gupta and colleagues present alarming results on the development of pre-treatment viral resistance to the most commonly used drugs to treat HIV infection in resource-limited countries. These findings complete the bleak picture of antiretroviral (ARV) treatment failure that is gradually emerging in these countries.

    April 1, 2018
    Lancet Infectious Diseases
  • A panel of European Medicines Agency on Friday recommended approval for GlaxoSmithKline’s two-drug regimen to treat HIV, the virus that causes AIDS. The new HIV treatment, Juluca, is a fixed-dose once-daily tablet that combines two previously approved drugs, dolutegravir and rilpivirine, and is available to patients who have been on a stable regimen for at least six months.

    March 23, 2018
    Reuters
  • In an effort to help people reduce their risk of getting HIV, the Thomas Jefferson Health District (TJHD serving the City of Charlottesville and Albemarle, Fluvanna, Greene, Louisa, and Nelson counties) will offer Pre-Exposure Prophylaxis (“PrEP”), an HIV prevention medication, at little to no cost.

    March 23, 2018
    NBC 29
  • Health minister Greg Hunt has announced that the HIV prevention drug PrEP will be listed on the Pharmaceutical Benefits Scheme (PBS) from April 1 at a cost to the government of $180 million over the forward estimates. Hunt said…Pre-Exposure Prophylaxis (PrEP), will be available for up to 32,000 people in Australia every year who are at medium to high risk of HIV transmission. It will cost a maximum of $39.50 per month.

    March 22, 2018
    Buzzfeed
  • Deputy President David Mabuza has called for an end to the stigma for HIV and AIDS, saying it is a disease that is the same as all others.

    March 22, 2018
    General
    Eyewitness News
  • South African women in a trial of a tenofovir-based vaginal gel were less protected against HIV if they had vaginal inflammation. In other words, as a form of HIV prevention, the gel may be compromised not only by poor adherence to the product but also by biological factors specific to individual women.

    March 22, 2018
    POZ
  • They [Salim and Quarraisha Abdool Karim] found that the girls in their teens and early 20s were getting infected by men who were, on average, about nine years older than they were. When they reached their late 20s, these women were infecting partners of their own age, who often didn’t realize it right away…..some of the men were then infecting the next crop of 16- and 17-year-old girls.

    March 22, 2018
    General
    The Atlantic
  • Robert Redfield's decades of scientific work is "peerless," said Health and Human Services Secretary Alex Azar in a statement released Wednesday. But others point to his checkered past, including allegations of scientific misconduct.

    March 21, 2018
    General
    Buzzfeed
  • Asian HIV advocates have warned reports that a new, drug-resistant HIV strain in the Philippines were ‘fake news’. A report in DW was first published on 9 March that an ‘aggressive and drug-resistant HIV subtype is behind skyrocketing HIV infection’….But HIV experts in the region have condemned the news reports labelling them ‘sensationalized’ and ‘fake news’.

    March 21, 2018
    General
    Gay Star News
  • "Development of an effective HIV vaccine will likely be necessary to achieve a durable end to the HIV pandemic," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases…. And Fauci is optimistic that it can happen because the vaccines don't need to be perfect to be helpful. An incremental improvement over the one tested in the Thai trial could have a major effect on spread of HIV, he says.

    March 21, 2018
    NPR
  • This year’s conference, held in Boston March 4 to 7, was notably lacking in blockbuster presentations but was nevertheless rich with science that will fuel efforts to better control the global HIV epidemic as well as the overlapping hepatitis C virus (HCV) epidemic.

    March 21, 2018
    POZ
  • More than two dozen sexual health clinics in England are now turning away gay men who are seeking to take HIV-preventing drugs, PinkNews has found….Many of the major clinics involved in the trial have already been forced to close recruitment to gay and bisexual men, after their capacity for trial places was quickly filled due to high demand.

    March 21, 2018
    PinkNews
  • More women are affected by human immunodeficiency virus (HIV) than any other life-threatening infectious agent. This makes it crucial to identify all factors increasing the risk of HIV infection. One risk factor may be injectable hormonal contraceptives.

    March 21, 2018
    The Conversation
  • The details of the case of a gay man who tested positive for HIV while apparently adhering to the daily Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) regimen remain hazy because there is insufficient information to determine whether he contracted a strain of the virus that is resistant to the two medications in the tablet, aidsmap reports.

    March 20, 2018
    POZ
  • Mombasa sex workers poured out to the streets on Tuesday to show support to the new drug that helps them not get infected AIDS by clients. The approximately 500 sex workers, including Lesbians, Gays, Transgender and Intersex (LGBTI), held a street demonstration in the coastal city to create awareness on the use of Pre-Exposure prophylaxis (PrEP) to curb HIV infections.

    March 20, 2018
    All Africa
  • People with HIV aged 60 and over in the United States are more than twice as likely to have an AIDS-defining illness or a CD4 cell count below 200 compared to under-40s, according to data presented to the recent Conference on Retroviruses and Opportunistic Infections (CROI 2018) in Boston.

    March 20, 2018
    General
    aidsmap

Published Research

Announcements